Differential regulations of blood pressure and perturbed metabolism by total ginsenosides and conventional antihypertensive agents in spontaneously hypertensive rats

被引:28
作者
Aa, Ji-ye [1 ]
Wang, Guang-ji [1 ]
Hao, Hai-ping [1 ]
Huang, Qing [2 ]
Lu, Yi-hong [2 ]
Yan, Bei [3 ]
Zha, Wei-bin [1 ]
Liu, Lin-sheng [1 ]
Kang, An [1 ]
机构
[1] China Pharmaceut Univ, Key Lab Drug Metab & Pharmacokinet, Nanjing 21009, Peoples R China
[2] Jiangsu Inst Food & Drug Control, Nanjing 21008, Peoples R China
[3] Minist Hlth, Beijing Hosp, Dept Pharmacol, Beijing 100730, Peoples R China
基金
中国国家自然科学基金;
关键词
metabonomics; hypertension; total ginsenosides; metabolic disorders; spontaneously hypertensive rats; FATTY-ACID; INSULIN-RESISTANCE; SPECTROSCOPIC DATA; METABONOMICS; GC/MS; IDENTIFICATION; VASODILATION; CHEMOMETRICS; MECHANISMS; INFUSION;
D O I
10.1038/aps.2010.86
中图分类号
O6 [化学];
学科分类号
070301 [无机化学];
摘要
Aim: To investigate the regulatory effects of total ginsenosides and the conventional antihypertensive agents (captopril, amlodipine, terazosin and hydrochlorothiazide) on the blood pressure and perturbed metabolism in spontaneously hypertensive rats (SHRs) and to analyze the cause-effect relationships between high blood pressure and the metabolic disorders of hypertension. Methods: SHRs were administrated with total ginsenosides or the antihypertensive agents for eight weeks. Systolic blood pressure (SP) was measured every week and low-molecular-weight compounds in blood plasma were quantitatively analyzed using a nontargeted high-throughput metabolomic tool: gas chromatography/time of flight mass spectrometry (GC/TOFMS). The metabolic patterns were evaluated using principal components analysis and potential markers of hypertension were identified. Results: Total ginsenosides and the antihypertensive agents differentially regulated SP and the metabolic pattern in SHRs. Total ginsenosides caused a progressive and prolonged reduction of SP and markedly normalized the perturbed metabolism with 14 of 27 (51.8%) markers of hypertension which were regulated toward normal. Total ginsenosides also reduced free fatty acids' level toward normal levels. In contrast, captopril, amlodipine and terazosin efficiently depressed SP, but had little effect on metabolic perturbation with only 8 (29.6%), 4 (14.8%), and 4 (14.8%) markers, respectively, which were regulated. Conclusion: The metabolic changes persisted when the blood pressure was lowered by the conventional antihypertensive agents, suggesting that hypertension may not be the cause of the metabolic perturbation in SHRs.
引用
收藏
页码:930 / 937
页数:8
相关论文
共 44 条
[1]
Identification of Cd36 (Fat) as an insulin-resistance gene causing defective fatty acid and glucose metabolism in hypertensive rats [J].
Aitman, TJ ;
Glazier, AM ;
Wallace, CA ;
Cooper, LD ;
Norsworthy, PJ ;
Wahid, FN ;
Al-Majali, KM ;
Trembling, PM ;
Mann, CJ ;
Shoulders, CC ;
Graf, D ;
St Lezin, E ;
Kurtz, TW ;
Kren, V ;
Pravenec, M ;
Ibrahimi, A ;
Abumrad, NA ;
Stanton, LW ;
Scott, J .
NATURE GENETICS, 1999, 21 (01) :76-83
[2]
Investigations into biochemical changes of genetic hypertensive rats using 1H nuclear magnetic resonance-based metabonomics [J].
Akira, K ;
Imachi, M ;
Hashimoto, T .
HYPERTENSION RESEARCH, 2005, 28 (05) :425-430
[3]
1H NMR-based metabonomic analysis of urine from young spontaneously hypertensive rats [J].
Akira, Kazuki ;
Masu, Shigenori ;
Imachi, Misako ;
Mitome, Hidemichi ;
Hashimoto, Miho ;
Hashimoto, Takao .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2008, 46 (03) :550-556
[4]
[Anonymous], MULTI MEGA VARIATE D
[5]
Brindle JT, 2002, NAT MED, V8, P1439, DOI 10.1038/nm802
[6]
Application of chemometrics to 1H NMR spectroscopic data to investigate a relationship between human serum metabolic profiles and hypertension [J].
Brindle, JT ;
Nicholson, JK ;
Schofield, PM ;
Grainger, DJ ;
Holmes, E .
ANALYST, 2003, 128 (01) :32-36
[7]
REVERSIBILITY OF THE EFFECTS ON LOCAL CIRCULATION OF HIGH LIPID CONCENTRATIONS IN BLOOD [J].
BULOW, J ;
MADSEN, J ;
HOJGAARD, L .
SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION, 1990, 50 (03) :291-296
[8]
Genome-wide mapping of human loci for essential hypertension [J].
Caulfield, M ;
Munroe, P ;
Pembroke, J ;
Samani, N ;
Dominiczak, A ;
Brown, M ;
Benjamin, N ;
Webster, J ;
Ratcliffe, P ;
O'Shea, S ;
Papp, J ;
Taylor, E ;
Dobson, R ;
Knight, J ;
Newhouse, S ;
Hooper, J ;
Lee, W ;
Brain, N ;
Clayton, D ;
Lathrop, GM ;
Farrall, M ;
Connell, J .
LANCET, 2003, 361 (9375) :2118-2123
[9]
The pressure of finding human hypertension genes: new tools, old dilemmas [J].
Charchar, F. J. ;
Zimmerli, L. U. ;
Tomaszewski, M. .
JOURNAL OF HUMAN HYPERTENSION, 2008, 22 (12) :821-828
[10]
Pharmaco-metabonomic phenotyping and personalized drug treatment [J].
Clayton, TA ;
Lindon, JC ;
Cloarec, O ;
Antti, H ;
Charuel, C ;
Hanton, G ;
Provost, JP ;
Le Net, JL ;
Baker, D ;
Walley, RJ ;
Everett, JR ;
Nicholson, JK .
NATURE, 2006, 440 (7087) :1073-1077